# Safety and Tolerability Evaluation of MaaT033

> **NCT04150393** · PHASE1 · COMPLETED · sponsor: **MaaT Pharma** · enrollment: 21 (actual)

## Conditions studied

- Hematologic Diseases
- Chemotherapy Effect

## Interventions

- **DRUG:** MaaT033 capsule

## Key facts

- **NCT ID:** NCT04150393
- **Lead sponsor:** MaaT Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-10-20
- **Primary completion:** 2021-12-13
- **Final completion:** 2021-12-13
- **Target enrollment:** 21 (ACTUAL)
- **Last updated:** 2022-04-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04150393

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04150393, "Safety and Tolerability Evaluation of MaaT033". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04150393. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*